Maze Therapeutics (NASDAQ:MAZE) Director Sells $464,043.28 in Stock

Key Points

• Richard Scheller, Director of Maze Therapeutics, sold 20,744 shares at an average price of $22.37, totaling approximately $464,043.
• Analysts have raised their price targets for Maze Therapeutics, with Guggenheim setting a new target of $34.00 and BTIG increasing theirs to $37.00, both maintaining a "buy" rating.
• Maze Therapeutics reported earnings of ($0.77) per share for the last quarter, slightly exceeding analysts’ expectations of ($0.79).

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) Director Richard H. Scheller sold 20,744 shares of the stock in a transaction on Monday, September 15th. The stock was sold at an average price of $22.37, for a total value of $464,043.28. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Maze Therapeutics Stock Down 2.3%

Shares of MAZE stock traded down $0.54 on Friday, hitting $22.94. 2,551,153 shares of the stock were exchanged, compared to its average volume of 703,763. Maze Therapeutics, Inc. has a one year low of $6.71 and a one year high of $25.50. The firm's 50 day moving average is $16.15 and its two-hundred day moving average is $12.67.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.77) earnings per share for the quarter, topping the consensus estimate of ($0.79) by $0.02.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Guggenheim increased their price objective on Maze Therapeutics from $19.00 to $34.00 and gave the stock a "buy" rating in a report on Monday, September 15th. Wall Street Zen raised Maze Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 16th. Wedbush assumed coverage on Maze Therapeutics in a report on Tuesday, July 8th. They set an "outperform" rating and a $17.00 price objective on the stock. HC Wainwright reissued a "buy" rating and set a $50.00 price objective on shares of Maze Therapeutics in a report on Thursday. Finally, BTIG Research increased their price objective on Maze Therapeutics from $30.00 to $37.00 and gave the stock a "buy" rating in a report on Friday, September 12th. Two equities research analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $32.67.

Institutional Trading of Maze Therapeutics

Large investors have recently modified their holdings of the business. Alphabet Inc. bought a new stake in shares of Maze Therapeutics during the 1st quarter valued at about $26,561,000. Invesco Ltd. bought a new stake in shares of Maze Therapeutics during the 1st quarter valued at about $226,000. Bank of New York Mellon Corp purchased a new position in shares of Maze Therapeutics during the 1st quarter valued at about $190,000. Nuveen LLC purchased a new position in shares of Maze Therapeutics during the 1st quarter valued at about $125,000. Finally, Octagon Capital Advisors LP purchased a new position in shares of Maze Therapeutics during the 1st quarter valued at about $5,153,000.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.